HN1

AcronymDefinition
HN1Hospitalman 1st Class (US Navy rating)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The design of a multiple drug combination for treating stage 1 bladder cancer depends on a strategy of inhibiting the highly expressed genes ADRM1, COPS5, PSMD8, SUMO2, CALR, PDIA3, DNAJB11, HSPA5, RPN1, CUL1, HSP90B1, KPNA2, PSMD12, ECT2, TK1, TUBA1C, HN1, and ENO1; activating the suppressed genes UBC, JUN, RARRES3, and FOS; and suppressing the drug's effect on the nondifferentially expressed genes BAG6, HUWE1, PAAF1, PSMD10, FAF2, PCYT1A, and PSMD10.
The design of a multiple drug combination for treating stage 4 bladder cancer depends on a strategy of inhibiting the highly expressed genes ADRM1, COPS5, PSMD8, SUMO2, RNF126, CALR, PDIA3, DNAJB11, HSPA5, RPN1, HSP90AA1, HSPA1B, METTL23, RARRES3, KPNA2, PSMD12, ECT2, JUN, TK1, TUBA1C, HN1, and ENO1; activating the suppressed genes BCL3, FOS, UBC, and GTF2A1; and suppressing the drug's effect on the nondifferentially expressed genes, which are the same as those in stage 1 bladder cancer.
Stage 1 bladder Stage 4 bladder cancer cancer The highly expressed ADRM1, COPS5, PSMD8, ADRM1, COPS5, PSMD8, genes for potential SUMO2, CALR, PDIA3, SUMO2, RNF126, CALR, inhibition strategy DNAJB11, HSPA5, RPN1, PDIA3, DNAJB11, of multiple drug CUL1, HSP90B1, KPNA2, HSPA5, RPN1, design PSMD12, ECT2, TK1, HSP90AA1, HSPA1B, TUBA1C, HN1, and ENO1 METTL23, RARRES3, KPNA2, PSMD12, ECT2, JUN, TK1, TUBA1C, HN1, and ENO1 The suppressed genes UBC, JUN, RARRES3, BCL3, FOS, UBC, and for potential and FOS GTF2A1 activation strategy of multiple drug design The BAG6, HUWE1, PAAF1, BAG6, HUWE1, PAAF1, nondifferentially PSMD10, FAF2, PCYT1A, PSMD10, FAF2, PCYT1A, expressed genes to and PSMD10 and PSMD10 avoid side-effect of multiple drug design The potential multiple drug combination